Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 28 versus SYEDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 28 versus SYEDA.
GENCEPT 10/11-28 vs SYEDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
Syeda is a combination of drospirenone and ethinyl estradiol, a contraceptive that suppresses gonadotropins, primarily inhibiting ovulation; drospirenone has antimineralocorticoid and antiandrogenic activity.
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
1 tablet (3 mg drospirenone / 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
Terminal elimination half-life of 12-15 hours; allows twice-daily dosing for sustained therapeutic levels.
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Urinary excretion (40-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for 15-25%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive